RNXT

RNXT

RenovoRx Inc

Net -9.86%top 1%Rev 32.59%top 1%Revenue grew 100% of years1Y
Hold

RenovoRx Inc. develops targeted combination therapies for cancer treatment, focusing on the delivery of chemotherapy through its proprietary device, RenovoCath. Its lead candidate is gemcitabine, currently in Phase III trials for advanced pancreatic cancer.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$1,018today

Score Overview

1 Year
Scoreโ€”
Net Growth-9.86%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth32.59%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-94.01%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend60%
Revenue Consistency

See the full market ranking โ†’

RenovoRx Inc fundamental performance

Across RenovoRx Inc's full reported history, from 2021 to 2025, revenue grew from $ 0.00 to $ 1M and net income went from -$ 6M to -$ 11M. Revenue increased in 60% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.12โ€”
1 Year2025-08-12
$ 1.101.82%
All Time2021-08-26
$ 7.26-84.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1M-$ 12M$ 12M
2025$ 1M-$ 11M$ 7M
2024$ 43K-$ 8M$ 7M
2023$ 0.00-$ 10M$ 1M
2022$ 0.00-$ 9M$ 6M
IPO2021$ 0.00-$ 6M$ 15M

Explore beyond RNXT

You're looking at RenovoRx Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies